RG
CARM

Redmile Group’s Carisma Therapeutics CARM Stock Holding History

Redmile Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-43,793
Closed -$2.64M – 50
2015
Q4 		$2.64M Buy
43,793
+1,375
+3% +$78.1K 0.2% 44
2015
Q3 		$2.04M Sell
42,418
-20,645
-33% -$1.27M 0.15% 47
2015
Q2 		$3.56M Buy
63,063
+51,063
+426% +$7.21M 0.29% 48
2015
Q1 		$2.14M Hold
12,000
– – 0.19% 49
2014
Q4 		$2.85M Buy
+12,000
New +$2.69M 0.31% 42

Other funds holding CARM

FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
FVFI
Flagship Ventures Fund IV Cambridge, Massachusetts $382M AUM
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Redmile Group's CARM Position: Q1 2016 in Review

Redmile Group sold out of Carisma Therapeutics (CARM) in Q1 2016, closing a stake of 43,793 shares — an estimated $2.64M sold.

Redmile Group first reported a position in CARM in Q4 2014 and held it in 5 quarters. The position peaked at $3.56M in Q2 2015. 23 funds tracked by Wall St. Rank hold CARM as of Q1 2016.

  • Redmile Group reported no remaining Carisma Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Redmile Group sold 43,793 Carisma Therapeutics shares in Q1 2016, an estimated $2.64M.
  • Redmile Group first reported a position in Carisma Therapeutics in Q4 2014 and held it in 5 quarters.
  • Redmile Group's Carisma Therapeutics position peaked at $3.56M in Q2 2015.
  • 23 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2016.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.